Results 181 to 190 of about 12,982 (196)

Alzheimer's Disease Co‐Pathology and Cognitive Impairment in Amyotrophic Lateral Sclerosis

Annals of Neurology, EarlyView.
Objectives Amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD) share neuropathological features, including tau, amyloid, and TDP‐43 pathology. This study investigated whether AD‐related pathological changes are associated with cognitive impairment ALS. Methods Cerebrospinal fluid (CSF total‐tau, phosphorylated‐tau, beta‐amyloid) and plasma
Elisabeth Kasper, Annaliis Lehto, Alexandra Jürs, Nina Nordmann, Oliver Peters, Julian Hellmann, Josef Priller, Eike Jakob Spruth, Gabor C. Petzold, Ina Voigt, Patrick Weydt, Sarah Bernsen, Elisabeth Dinter, Björn Falkenburger, René Günther, Emrah Düzel, Wenzel Glanz, Matthis Synofzik, Lukas Beichert, Annika Spottke, Michael Wagner, Frederic Brosseron, Matthias C. Schmid, Annett Halle, Jochen Herms, Anja Schneider, Stefan Teipel, Johannes Prudlo, Manuela Neumann, Andreas Hermann   +29 more
wiley   +1 more source

NUAK2 Inhibition Enhances Macromolecular Drug Delivery in a 3D Fibrotic Model of the Pancreatic Tumor Microenvironment

Advanced NanoBiomed Research, EarlyView.
Using a 3D cell culture model of the fibrotic barrier in pancreatic cancer, this work shows that inhibiting NUAK2 kinase in pancreatic stellate cells enhances macromolecular drug delivery. Mechanistically, NUAK2 inhibition disrupted actin stress fiber assembly to downregulate collagen I expression, thus enhancing macromolecular permeability.
Misaki Nakamura, Hiroyoshi Y. Tanaka, Mayu Ohira, Haruko Ohta‐Okano, Reika Nakamura, Yu Seno, Saaya Yara, Sakura Fujita, Daichi Shibata, Masaya Yamamoto, Shinichi Toyooka, Kensuke Osada, Horacio Cabral, Atsushi Masamune, Mitsunobu R. Kano   +14 more
wiley   +1 more source

Heterogenous Model of Temozolomide Resistance in Glioblastoma Reveals Phenotypic Shifts in Drug Response and Migratory Potential

Advanced NanoBiomed Research, EarlyView.
Glioblastoma mortality is driven by cell invasion and therapeutic resistance. We report a cancer engineering approach to evaluate the behavior of heterogeneous cohorts of temozolomide resistant and responsive GBM cells. We show the effect of physiologically‐relevant metronomic dosing on ensemble drug response and invasion.
Victoria A. Kriuchkovskaia, Ela K. Eames, Sydney A. McKee, Paul J. Hergenrother, Rebecca B. Riggins, Brendan A. C. Harley   +5 more
wiley   +1 more source

Liposomal Delivery of L‐2‐Hydroxyglutarate for Targeting Epigenetic Dysregulation in Osteoarthritis

Advanced NanoBiomed Research, EarlyView.
Osteoarthritis involves cartilage degeneration, inflammation, and epigenetic dysregulation. A liposomal formulation of the TET1 inhibitor L‐2‐hydroxyglutarate to overcome rapid joint clearance was developed. The formulation showed good physicochemical properties, reduced inflammatory and catabolic gene expression in chondrocytes, and alleviated ...
Denise Murgia, Akshay Pandey, Raffaele Spanò, Bianca Martins Estevão, Roberto Palomba, Greta Avancini, Tamaghna Gupta, Ana Maria Lopez Estevez, Stuart B. Goodman, Nidhi Bhutani, Paolo Decuzzi   +10 more
wiley   +1 more source

Interleukin‐18 Levels Are Associated With Disease Course in Patients With Still Disease Treated With Interleukin‐1 Inhibitors

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the prognostic utility of circulating interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in patients with Still disease (SD) receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan, Manuela Pardeo, Ivan Caiello, Claudia Bracaglia, Arianna De Matteis, Valentina Matteo, Elena Loricchio, Fabrizio De Benedetti, Giusi Prencipe   +8 more
wiley   +1 more source

Long‐Term Outcomes of Reduced‐Intensity Conditioning Hematopoietic Stem Cell Transplantation for Patients With Systemic Sclerosis With Impaired Cardiac Function

Arthritis &Rheumatology, EarlyView.
Objective High‐intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced systemic sclerosis (SSc). The role of reduced‐intensity conditioning (RIC) before AHSCT in this population remains unclear.
Yonatan Lean, Carrie Richardson, Anthony J. Esposito, Katy Bedjeti, George E. Georges   +4 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity

British Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 1A2 (CYP1A2) exhibits substantial interindividual variability, necessitating appropriate phenotyping strategies for personalized pharmacotherapy. This study evaluated endogenous melatonin partial metabolic clearance (CLm(MEL)), calculated from urinary 6‐hydroxymelatonin (6‐O‐MEL) excretion and plasma melatonin (MEL) exposure, as a ...
Akitomo Yokokawa, Hayato Shimazaki, Shunji Igarashi, Yoshiki Tagawa, Naoki Hisada, Hiromi Shibasaki   +5 more
wiley   +1 more source

Scalable desolvation synthesis, storage stability, and comprehensive biophysical characterization of human hemoglobin nanoparticles as a potential hemoglobin‐based oxygen carrier

Biotechnology Progress, EarlyView.
This work describes the development of human hemoglobin nanoparticles using an anti‐solvent precipitation synthesis method as a potential next generation hemoglobin‐based oxygen carrier. The hemoglobin nanoparticles are uniform in size and shape, hemocompatible, stable at various storage conditions, and demonstrate a scalable synthesis technique ...
Alisyn Greenfield, Andre F. Palmer
wiley   +1 more source